Jump to navigation Jump to search
ICD-10 M85.8
DiseasesDB 30719
MeSH D015576

WikiDoc Resources for Hyperostosis


Most recent articles on Hyperostosis

Most cited articles on Hyperostosis

Review articles on Hyperostosis

Articles on Hyperostosis in N Eng J Med, Lancet, BMJ


Powerpoint slides on Hyperostosis

Images of Hyperostosis

Photos of Hyperostosis

Podcasts & MP3s on Hyperostosis

Videos on Hyperostosis

Evidence Based Medicine

Cochrane Collaboration on Hyperostosis

Bandolier on Hyperostosis

TRIP on Hyperostosis

Clinical Trials

Ongoing Trials on Hyperostosis at Clinical Trials.gov

Trial results on Hyperostosis

Clinical Trials on Hyperostosis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Hyperostosis

NICE Guidance on Hyperostosis


FDA on Hyperostosis

CDC on Hyperostosis


Books on Hyperostosis


Hyperostosis in the news

Be alerted to news on Hyperostosis

News trends on Hyperostosis


Blogs on Hyperostosis


Definitions of Hyperostosis

Patient Resources / Community

Patient resources on Hyperostosis

Discussion groups on Hyperostosis

Patient Handouts on Hyperostosis

Directions to Hospitals Treating Hyperostosis

Risk calculators and risk factors for Hyperostosis

Healthcare Provider Resources

Symptoms of Hyperostosis

Causes & Risk Factors for Hyperostosis

Diagnostic studies for Hyperostosis

Treatment of Hyperostosis

Continuing Medical Education (CME)

CME Programs on Hyperostosis


Hyperostosis en Espanol

Hyperostosis en Francais


Hyperostosis in the Marketplace

Patents on Hyperostosis

Experimental / Informatics

List of terms related to Hyperostosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Hyperostosis is an excessive growth of bone. It may lead to exostosis. It occurs in many musculoskeletal disorders.

It is the thickening of the cortical bone.

Hyperphosphatemia-hyperostosis syndrome (HHS) is a rare autosomal recessive metabolic disorder characterized by elevated serum phosphate levels and radiological evidence of cortical hyperostosis.[1] HHS is caused by mutations in GALNT3.[2]


Drug Side Effect


  1. Frishberg Y, Topaz O, Bergman R, Behar D, Fisher D, Gordon D, Richard G, Sprecher E (2005). "Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders". J Mol Med. 83 (1): 33–8. PMID 15599692. Unknown parameter |month= ignored (help)
  2. Ichikawa S, Guigonis V, Imel EA, Courouble M, Heissat S, Henley JD, Sorenson AH, Petit B, Lienhardt A, Econs MJ (2007). "Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations". J Clin Endocrinol Metab. 92 (5): 1943–7. PMID 17311862. Unknown parameter |month= ignored (help)

See also


Template:WikiDoc Sources